

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SUNSHINE LAKE PHARMA CO., LTD.**

**廣東東陽光藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6887)**

**POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING  
AND ELECTION OF EMPLOYEE DIRECTOR  
TO THE SECOND SESSION OF THE BOARD**

Reference is made to the circular of Sunshine Lake Pharma Co., Ltd. (the “**Company**”) dated 28 May 2026 (the “**Circular**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Circular.

**POLL RESULTS OF THE AGM**

The AGM was held on Thursday, 18 June 2026 at Conference Room, 3/F, Sales Building, Dongyangguang Scientific Park, No. 368 Zhen An Zhong Road, Chang’an County, Dongguan, Guangdong Province, the PRC. The AGM was duly and validly convened in accordance with the Company Law and other relevant laws and regulations of the PRC, the Hong Kong Listing Rules and the Articles of Association.

On the date of the AGM, the total number of Shares issued by the Company was 576,656,047 Shares, comprising a total of 255,552,907 Domestic Shares and a total of 321,103,140 H Shares issued, among which 677,600 H Shares were Treasury Shares. Holder of Treasury Shares was not entitled to vote and abstain from voting on the resolutions proposed at the AGM. Save as disclosed above, as of the date of the AGM, there were (a) no Treasury Shares held by the Company (including any Treasury Shares held or deposited with the Central Clearing and Settlement System); and (b) no repurchased Shares which are pending cancellation and should be excluded from the total number of issued Shares for the purpose of the AGM.

The total number of Shares entitling the Shareholders to attend the AGM and to vote for, against or abstain from voting on the resolutions proposed at the AGM is 575,978,447 Shares (comprising 255,552,907 Domestic Shares and 320,425,540 H Shares). Shareholders (either in person or by proxy) present at the AGM held 366,077,100 Shares carrying voting rights, representing approximately 63.5574% of the total number of issued Shares carrying voting rights.

No Shareholder was required under the Hong Kong Listing Rules to abstain from voting on the resolutions proposed at the AGM. There were no Shares entitling the holder to attend and abstain from voting in favour of the proposed resolutions at the AGM pursuant to Rule 13.40 of the Hong Kong Listing Rules. No Shareholder has indicated in the Circular that they intend to vote against or abstain from voting on the proposed resolutions.

The proposed resolutions were voted on by poll. The Company's H Share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the counting of votes at the AGM. Two shareholder representatives and a supervisor of the Company also acted as scrutineers for the vote-taking and counting.

All the Directors have attended the AGM.

Please refer to the Circular for full text of the resolutions. The poll results of the AGM are as follows:

Ordinary Resolutions		For		Against		Abstain	
		Number of Shares	Percentage (%)	Number of Shares	Percentage (%)	Number of Shares	Percentage (%)
1.	To consider and approve the audited consolidation financial statements of the Company and its subsidiaries, and the report of the auditor of the Company, for the year ended 31 December 2025.	366,025,345	99.9859%	0	0.0000	51,655	0.0141%
2.	To consider and approve the report of the Board of Directors for the year ended 31 December 2025.	366,025,345	99.9859%	0	0.0000%	51,655	0.0141%
3.	To consider and approve the report of the Board of Supervisors for the year ended 31 December 2025.	366,025,345	99.9859%	0	0.0000%	51,655	0.0141%
4.	To consider and approve the 2025 annual report of the Company.	366,025,345	99.9859%	0	0.0000%	51,655	0.0141%
5.	To consider and approve the Resolution on the Election of the second session of the Board.						
5.01	To elect Dr. Zhang Yingjun as an executive Director of the second session of the Board of Directors.	353,418,043	96.5420%	12,658,957	3.4580%	0	0.0000%
5.02	To elect Mr. Jiang Juncai as an executive Director of the second session of the Board of Directors.	353,575,128	96.5849%	12,501,872	3.4151%	0	0.0000%
5.03	To elect Mr. Zhang Yushuai as a non-executive Director of the second session of the Board of Directors.	353,575,128	96.5849%	12,501,872	3.4151%	0	0.0000%

Ordinary Resolutions		For		Against		Abstain	
		Number of Shares	Percentage (%)	Number of Shares	Percentage (%)	Number of Shares	Percentage (%)
5.04	To elect Mr. Tang Xinfu as a non-executive Director of the second session of the Board of Directors.	353,432,486	96.5459%	12,644,514	3.4541%	0	0.0000%
5.05	To elect Mr. Zhu Yingwei as a non-executive Director of the second session of the Board of Directors.	353,575,128	96.5849%	12,501,872	3.4151%	0	0.0000%
5.06	To elect Dr. Li Wenjia as a non-executive Director of the second session of the Board of Directors.	353,575,128	96.5849%	12,501,872	3.4151%	0	0.0000%
5.07	To elect Dr. Li Xintian as an independent non-executive Director of the second session of the Board of Directors.	353,618,977	96.5969%	12,458,023	3.4031%	0	0.0000%
5.08	To elect Dr. Ma Dawei as an independent non-executive Director of the second session of the Board of Directors.	353,618,977	96.5969%	12,458,023	3.4031%	0	0.0000%
5.09	To elect Dr. Lin Aimei as an independent non-executive Director of the second session of the Board of Directors.	353,564,173	96.5819%	12,512,827	3.4181%	0	0.0000%
5.10	To elect Dr. Ye Tao as an independent non-executive Director of the second session of the Board of Directors.	353,618,977	96.5969%	12,458,023	3.4031%	0	0.0000%
6.	To consider and approve the remuneration plan for Directors.	366,077,000	100.0000%	0	0.0000%	0	0.0000%
7.	To consider and approve the proposed re-appointment of KPMG as the auditors of the Company for 2026, and to authorize the Board of Directors to fix the remuneration of KPMG for 2026.	366,055,855	99.9942%	21,145	0.0058%	0	0.0000%

As more than half of the votes from the Shareholders (including their proxies) attending the AGM were cast in favor of resolutions no. 1 to 7, these resolutions were duly passed as ordinary resolutions.

Special Resolutions		For		Against		Abstain	
		Number of Shares	Percentage (%)	Number of Shares	Percentage (%)	Number of Shares	Percentage (%)
8.	To consider and approve the Resolution on the Amendments to the Articles of Association.	366,077,000	100.0000%	0	0.0000%	0	0.0000%
9.	To consider and approve the Resolution on the Amendments to the Rules of Procedure for General Meetings of the Company.	366,077,000	100.0000%	0	0.0000%	0	0.0000%
10.	To consider and approve the Resolution on the Amendments to the Rules of Procedure for the Board of Directors of the Company.	366,077,000	100.0000%	0	0.0000%	0	0.0000%
11.	To consider and approve the grant of a general mandate to the Board to allot, issue and dispose of additional Shares and/or sell Treasury Shares of the Company during the Relevant Period in an amount not exceeding 20% of the total number of issued Shares of the Company (excluding Treasury Shares) on the date of passing of this resolution, and to authorise the Board to (1) make corresponding amendments to the Articles of Association of the Company as appropriate to reflect the new share capital structure after the allotment or issue of Shares; and (2) formulate and implement any specific share issue schemes pursuant to any exercise of the general mandate.	354,101,660	96.7287%	11,973,053	3.2706%	2,287	0.0006%
12.	To consider and approve the granting of a general mandate to the Board to repurchase issued Shares not exceeding 10% of the total issued Shares (excluding Treasury Shares) of the Company as at the date of passing this resolution, during the Relevant Period.	366,074,713	99.9993%	0	0.0000%	2,287	0.0006%

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the AGM were cast in favour of resolutions no. 8 to 12, these resolutions were duly passed as special resolutions.

## **ELECTION OF EMPLOYEE DIRECTOR TO THE SECOND SESSION OF THE BOARD**

Upon the conclusion of the AGM, the term of office of the first session of the Board expired. The Board hereby announces that in accordance with the Company Law and the relevant regulations, on 18 June 2026, upon election by the employee representative meeting of the Company, Mr. Zhang Zhiyong was elected as the employee Director (executive Director) of the second session of the Board, with his term of office commencing from the date of approval of the second session of the Board by the AGM of the Company (i.e. 18 June 2026) and up to the expiry of the term of the second session of the Board.

The biographical details of Mr. Zhang Zhiyong is set out as follows:

Mr. Zhang Zhiyong, aged 47, joined our Group in February 2007 and was appointed as the deputy general manager of the Company on 19 June 2023, mainly responsible for drug production quality control.

Mr. Zhang has approximately 18 years of extensive experience in the field of pharmaceutical production quality management. Mr. Zhang has served as the deputy manager of our Company since July 2023, mainly responsible for pharmaceutical production quality management. From January 2022 to June 2023, he served as the executive director of Guangdong HEC Biopharmaceutical Co., Ltd\* (廣東東陽光生物製劑有限公司), mainly responsible for company management and decision-making. Mr. Zhang also served as the chairman and general manager of Ruyuan HEC Pharmaceutical Co., Ltd.\* (乳源東陽光藥業有限公司) from March 2010 to February 2023, and the head of the formulation department and deputy head of the drug research department of the Company from April 2012 to August 2017. From February 2007 to July 2013, he served as the head of the preparation team of the pharmaceutical factory of the Company, mainly responsible for the preparation of the pharmaceutical production and quality management system. From June 2015 to January 2021, Mr. Zhang also served as the general manager of the Company.

Mr. Zhang obtained a bachelor's degree in pharmaceutical engineering from Hubei College of Traditional Chinese Medicine in June 2002.

The Company has entered into an employment contract with Mr. Zhang. Mr. Zhang will receive remuneration based on his senior management position within the Company, but will not receive remuneration in respect of his role as an employee Director. The Company will disclose the total remuneration received by the Directors in the annual report of the Company accordingly.

Mr. Zhang has confirmed that, saved as disclosed above, as of the date of this announcement, he: (1) does not hold any other position with the Company or any of its subsidiaries and has not been a director in any other listed companies during the past three years; (2) he has no relationship with any other Directors, senior management, controlling or substantial shareholders of the Company; and (3) he does not have, or is not deemed to have, any interest in the Shares or underlying Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Mr. Zhang has also confirmed that there is no other information in relation to his appointment that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Hong Kong Listing Rules, and there is no other matter in relation to his appointment that needs to be brought to the attention of the Hong Kong Stock Exchange and Shareholders.

By Order of the Board  
**Sunshine Lake Pharma Co., Ltd.**  
**Dr. ZHANG Yingjun**  
*Chairman of the board*

Dongguan, the PRC  
18 June 2026

*As at the date of this announcement, the executive Directors are Dr. ZHANG Yingjun, Mr. JIANG Juncai and Mr. ZHANG Zhiyong (employee Director), the non-executive Directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei and Dr. LI Wenjia, and the independent non-executive Directors are Dr. LI Xintian, Dr. MA Dawei, Dr. LIN Aimei and Dr. YE Tao.*